INTEGRA LIFESCIENCES HLDGS C's ticker is IART and the CUSIP is 457985208. A total of 274 filers reported holding INTEGRA LIFESCIENCES HLDGS C in Q4 2021. The put-call ratio across all filers is 3.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $229,640 | +2.4% | 4,000 | 0.0% | 0.04% | -4.7% |
Q4 2022 | $224,280 | +3.8% | 4,000 | 0.0% | 0.04% | +13.2% |
Q2 2022 | $216,000 | -16.0% | 4,000 | 0.0% | 0.04% | +5.6% |
Q1 2022 | $257,000 | -4.1% | 4,000 | 0.0% | 0.04% | +12.5% |
Q4 2021 | $268,000 | -2.2% | 4,000 | 0.0% | 0.03% | -11.1% |
Q3 2021 | $274,000 | +0.4% | 4,000 | 0.0% | 0.04% | -7.7% |
Q2 2021 | $273,000 | -1.1% | 4,000 | 0.0% | 0.04% | -15.2% |
Q1 2021 | $276,000 | +6.2% | 4,000 | 0.0% | 0.05% | 0.0% |
Q4 2020 | $260,000 | +11.6% | 4,000 | 0.0% | 0.05% | -16.4% |
Q4 2019 | $233,000 | -2.9% | 4,000 | 0.0% | 0.06% | -6.8% |
Q3 2019 | $240,000 | +7.6% | 4,000 | 0.0% | 0.06% | +11.3% |
Q2 2019 | $223,000 | 0.0% | 4,000 | 0.0% | 0.05% | -1.9% |
Q1 2019 | $223,000 | -15.2% | 4,000 | 0.0% | 0.05% | -16.9% |
Q3 2018 | $263,000 | +1.9% | 4,000 | 0.0% | 0.06% | +12.1% |
Q2 2018 | $258,000 | +16.7% | 4,000 | 0.0% | 0.06% | +16.0% |
Q1 2018 | $221,000 | +9.4% | 4,000 | 0.0% | 0.05% | -7.4% |
Q3 2017 | $202,000 | -7.3% | 4,000 | 0.0% | 0.05% | -8.5% |
Q2 2017 | $218,000 | – | 4,000 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VeriStar Capital Management LP | 268,000 | $10,234,920 | 8.72% |
Madison Avenue Partners, LP | 964,667 | $36,840,633 | 5.23% |
Pavadi Capital LLC | 99,999 | $3,818,962 | 4.97% |
KESTREL INVESTMENT MANAGEMENT CORP | 122,450 | $4,676 | 2.96% |
Sapience Investments, LLC | 245,700 | $9,383,283 | 2.26% |
Ellsworth Advisors, LLC | 102,500 | $3,882,700 | 1.38% |
Point72 Europe (London) LLP | 464,462 | $17,737,804 | 1.09% |
COOKE & BIELER LP | 2,714,194 | $103,655,069 | 1.01% |
TANDEM CAPITAL MANAGEMENT CORP /ADV | 75,586 | $2,886,630 | 0.99% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,126,827 | $43,033,523 | 0.95% |